Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

FLEETPARTNERS GROUP LIMITED Capital/Financing Update 2019

Jul 18, 2019

64940_rns_2019-07-18_9cbbf16a-7f92-487e-9968-e24fe97ba3ad.pdf

Capital/Financing Update

Open in viewer

Opens in your device viewer

Rule 2.7, 3.10.3, 3.10.4, 3.10.5

Appendix 3B

New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

Introduced 01/07/96 Origin Appendix 5 Amended 01/07/98, 01/09/99, 01/07/00, 30/09/01, 11/03/02, 01/01/03, 24/10/05, 01/08/12, 04/03/13

Name of entity

Eclipx Group Limited (Eclipx) (ASX: ECX)

ABN

85 131 557 901

We (the entity) give ASX the following information.

Part 1 - All issues

You must complete the relevant sections (attach sheets if there is not enough space).

1
+Class of+securities issued or to
be issued
2
Number of+securities issued or
to be issued (if known) or
maximum number which may
be issued
3
Principal terms of the+securities
(e.g. if options, exercise price
and expiry date; if partly paid
+securities,
the
amount
outstanding and due dates for
payment;
if
+convertible
securities, the conversion price
and dates for conversion)
Options (unquoted)
5,420,679 Options issued
3,584,500 Options forfeited
863,500 Rights forfeited
Options Issued

3,448,275 Options issued

Each option is a right to acquire a fully
paid ordinary share on a one-for-one
basis at the exercise price (or to receive
the cash equivalent value), subject to
a vesting condition (related to continued
employment until 17 July 2022) being
satisfied.

Exercise price: $1.60

Exercise period: A period commencing on
the day following the vesting date and
ending on 17 July 2023

Expirydate: 17 July2023
  • If a change of control transaction involving more than 50% of Eclipx’s issued shares occurs, all unvested Options will vest in full, subject to the Board determining that a different treatment should apply.

Options Issued

  • 1,972,404 Options issued

  • Each option is a right to acquire a fully paid ordinary share on a one-for-one basis at the exercise price (or to receive the cash equivalent value), subject to a vesting condition (related to continued employment until 23 May 2022) being satisfied.

  • “True up” grants issued on terms described in the ASX announcement of 13 May 2019

  • Exercise price: $1.20

  • Exercise period: A period commencing on the day following the vesting date and ending on 23 May 2023

  • Expiry date: 23 May 2023

  • If a change of control transaction involving more than 50% of Eclipx’s issued shares occurs, all unvested Options will vest in full, subject to the Board determining that a different treatment should apply.

Options Forfeited

A total of 3,584,500 Options (various tranches) forfeited. Options previously held by former Executives (including CFO) and staff no longer with Eclipx.

Rights Forfeited

A total of 863,500 Rights (various tranches) forfeited. Rights previously held by former Executives (including CFO) and staff no longer with Eclipx.

  • See chapter 19 for defined terms.

Appendix 3B Page 2

04/03/2013

4
Do the+securities rank equally
in all respects from the+issue
date with an existing+class of
quoted+securities?
If the additional+securities do
not rank equally, please state:
 the date from which they do
 the extent to which they
participate
for
the
next
dividend, (in the case of a
trust,
distribution)
or
interest payment
 the extent to which they do
not rank equally, other than
in
relation
to
the
next
dividend,
distribution
or
interest payment
5
Issue price or consideration
6
Purpose of the issue
(If issued as consideration for
the acquisition of assets, clearly
identify those assets)
6a
Is the entity an+eligible entity
that
has
obtained
security
holder approval under rule 7.1A?
If Yes, complete sections 6b – 6h
in relation to the+securities the
subject of this Appendix 3B, and
comply with section 6i
6b
The date the security holder
resolution under rule 7.1A was
passed
6c
Number of+securities issued
without security holder approval
under rule 7.1
6d
Number of+securities issued
with security holder approval
under rule 7.1A
1. N/A
2. N/A
Options
are
issued
for
nil
financial
consideration under the Eclipx Group Limited
LongTerm Incentive Plan(ECX LTIP)
Options
are
issued
for
nil
financial
consideration under the ECX LTIP.
No
N/A
N/A
N/A
6e
Number of+securities issued
with security holder approval
under rule 7.3, or another
specific security holder approval
(specify date of meeting)
6f
Number of+securities issued
under an exception in rule 7.2
6g
If+securities issued under rule
7.1A, was issue price at least 75%
of 15 day VWAP as calculated
under rule 7.1A.3? Include the
+issue date and both values.
Include the source of the VWAP
calculation.
6h
If+securities were issued under
rule
7.1A
for
non-cash
consideration, state date on
which
valuation
of
consideration was released to
ASX Market Announcements
6i
Calculate the entity’s remaining
issue capacity under rule 7.1 and
rule 7.1A – complete Annexure 1
and release to ASX Market
Announcements
7
+Issue dates
Note The issue date may be prescribed by
ASX (refer to the definition of issue date in
rule 19 12) For example, the issue date for a
pro rata entitlement issue must comply with
the applicable timetable in Appendix 7A
Cross reference item 33 of Appendix 3B
8
Number
and
+class
of
all
+securities
quoted
on
ASX
(_including_the
+securities in
section 2 if applicable)
9
Number
and
+class
of
all
+securities not quoted on ASX
(_including_the
+securities in
section 2 if applicable)
N/A
N/A

N/A
N/A
N/A
18 July 2019
24 May 2019
Number +Class
319,636,693 Fully
paid
ordinary
shares
485,000
700,000
Non-Executive Director
Options (2.65 Exp.
21/04/2020)
FY15 LTI Options ($2.30
Exp. 21/04/2020)
  • See chapter 19 for defined terms.

Appendix 3B Page 4

04/03/2013

420,000
1,765,000
312,500
1,000,000
4,120,000
542,000
3,230,000
900,000
415,000
158,000
632,000
200,000
300,000
1,055,000
835,000
FY16 LTI PRF Rights
(Exp. 10/11/2020)
FY16 LTI Options ($3.06
Exp. 10/11/2020)
PRF Rights (Exp.
19/05/2021)
FY17 LTI Options
($3.8048 Exp.
04/09/2021)
FY17 LTI Options ($3.60
Exp 4/11/2021)
FY17 LTI PRF Rights
(Exp. 4/11/2021)
FY18 LTI Options ($4.18
Exp. 8/11/2022)
FY18 LTI PRF Rights
(Exp. 8/11/2022)
PRF Rights (Exp.
18/12/2022)
FY18 LTI PRF Rights
(Exp. 8/11/2022)
FY18 LTI Options ($4.18
Exp. 8/11/2022)
SRV Rights (Exp.
16/8/23)
Options ($2.05 Exp.
16/8/23)
FY19 LTI PRF Rights
(Exp. 16/12/2023)
FY19 LTI SRV Rights
(Exp. 16/12/2023)
4,800,000
9,204,547
1,127,215
563,607
208,333
104,167
3,448,275
FY19 LTI Options
($2.54 Exp. 16/12/2023)
FY19 Special Options
($1.20 Exp. 23/05/2023)
November 2019
Retention Options
($1.20 Exp. 15/05/2021)
May 2020 Retention
Options
($1.20 Exp. 15/05/2021)
November 2019
Retention Rights
(Exp. 15/05/2021)
May 2020 Retention
Rights
(Exp. 15/05/2021)
FY19 Options
($1.60 Exp. 17/07/2023)

10 Dividend policy (in the case of a N/A trust, distribution policy) on the increased capital (interests)

Part 2 - Pro rata issue

11 Is security holder approval N/A required? 12 Is the issue renounceable or nonN/A renounceable? 13 Ratio in which the[+] securities N/A will be offered 14 +Class of +securities to which the N/A offer relates 15 +Record date to determine N/A entitlements

  • See chapter 19 for defined terms.

Appendix 3B Page 6

04/03/2013

16
Will
holdings
on
different
registers (or subregisters) be
aggregated
for
calculating
entitlements?
17
Policy for deciding entitlements
in relation to fractions
18
Names of countries in which the
entity has security holders who
will not be sent new offer
documents
Note Security holders must be told how their
entitlements are to be dealt with
Cross reference rule 7 7
19
Closing
date
for
receipt
of
acceptances or renunciations
20
Names of any underwriters
21
Amount of any underwriting fee
or commission
22
Names of any brokers to the
issue
23
Fee or commission payable to the
broker to the issue
24
Amount of any handling fee
payable to brokers who lodge
acceptances or renunciations on
behalf of security holders
25
If the issue is contingent on
security holders’ approval, the
date of the meeting
26
Date entitlement and acceptance
form and offer documents will be
sent to persons entitled
27
If the entity has issued options,
and the terms entitle option
holders
to
participate
on
exercise, the date on which
notices will be sent to option
holders
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
28
Date rights trading will begin (if
applicable)
29
Date rights trading will end (if
applicable)
30
How do security holders sell
their entitlements_in full_through
a broker?
31
How do security holders sell_part_
of their entitlements through a
broker
and
accept
for
the
balance?
32
How do security holders dispose
of their entitlements (except by
sale through a broker)?
33
+Issue date
N/A
N/A
N/A
N/A
N/A
N/A

Part 3 - Quotation of securities

You need only complete this section if you are applying for quotation of securities

  • 34 Type of[+] securities ( tick one )

  • (a) +Securities described in Part 1

  • (b)[All other ][+][securities ]

Example restricted securities at the end of the escrowed period, partly paid securities that become fully paid, employee incentive share securities when restriction ends, securities issued on expiry or conversion of convertible securities

Entities that have ticked box 34(a)

Additional securities forming a new class of securities

Tick to indicate you are providing the information or documents

35 If the[+] securities are[+] equity securities, the names of the 20 largest holders of the additional[+] securities, and the number and percentage of additional[+] securities held by those holders

  • See chapter 19 for defined terms.

Appendix 3B Page 8

04/03/2013

36 If the[+] securities are[+] equity securities, a distribution schedule of the additional +securities setting out the number of holders in the categories 1 - 1,000 1,001 - 5,000 5,001 - 10,000 10,001 - 100,000 100,001 and over

  • 37 A copy of any trust deed for the additional[+] securities

Entities that have ticked box 34(b)

  • 38 Number of[+] securities for which +quotation is sought

  • 39 +Class of +securities for which quotation is sought

  • 40 Do the[+] securities rank equally in all respects from the[+] issue date with an existing[+] class of quoted +securities?

If the additional[+] securities do not rank equally, please state:

  • the date from which they do

  • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment

  • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment

  • 41 Reason for request for quotation now

  • Example In the case of restricted securities, end of restriction period

(if issued upon conversion of another[+] security, clearly identify that other[+] security)

Number +Class

  • 42 Number and +class of all +securities quoted on ASX ( including the[+] securities in clause 38)

  • See chapter 19 for defined terms.

Appendix 3B Page 10

04/03/2013

Quotation agreement

  • 1 +Quotation of our additional +securities is in ASX’s absolute discretion. ASX may quote the[+] securities on any conditions it decides.

  • 2 We warrant the following to ASX.

  • The issue of the[+] securities to be quoted complies with the law and is not for an illegal purpose.

  • There is no reason why those[+] securities should not be granted +quotation.

  • An offer of the[+] securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

  • Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any[+] securities to be quoted and that no-one has any right to return any[+] securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the[+] securities be quoted.

  • If we are a trust, we warrant that no person has the right to return the +securities to be quoted under section 1019B of the Corporations Act at the time that we request that the[+] securities be quoted.

  • 3 We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.

  • 4 We give ASX the information and documents required by this form. If any information or document is not available now, we will give it to ASX before +quotation of the +securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

Sign here: Date: 19 July 2019 Company Secretary

Print name: Matthew Sinnamon

  • See chapter 19 for defined terms.

Appendix 3B Page 11

04/03/2013